Must-See Earnings Estimates NASDAQ:CCNC, NASDAQ:MOTS, NASDAQ:EYEG, NYSE:TCI

CODE CHAIN NEW CONTINENT (NASDAQ:CCNC) EARNINGS INFORMATION (NASDAQ:CCNC)

Code Chain New Continent last posted its quarterly earnings results on May 14th, 2021. The reported ($0.46) earnings per share for the quarter. The business had revenue of $3.38 million for the quarter. Code Chain New Continent has generated $0.00 earnings per share over the last year.

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN CODE CHAIN NEW CONTINENT? (NASDAQ:CCNC)

Wall Street analysts have given Code Chain New Continent a “N/A” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Code Chain New Continent wasn’t one of them. MarketBeat thinks these five companies may be even better buys.

MOTUS GI (NASDAQ:MOTS) EARNINGS INFORMATION (NASDAQ:MOTS)

Motus GI last posted its earnings results on August 12th, 2021. The reported ($0.10) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.11) by $0.01. Motus GI has generated ($0.60) earnings per share over the last year (($0.65) diluted earnings per share). Earnings for Motus GI are expected to grow in the coming year, from ($0.50) to ($0.41) per share. Motus GI has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Thursday, November 11th, 2021 based off prior year’s report dates.

IS MOTUS GI A BUY RIGHT NOW? (NASDAQ:MOTS)

3 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for Motus GI in the last year. There are currently 3 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” Motus GI stock.
Motus GI

EYEGATE PHARMACEUTICALS (NASDAQ:EYEG) EARNINGS INFORMATION (NASDAQ:EYEG)

EyeGate Pharmaceuticals last announced its earnings results on August 12th, 2021. The specialty pharmaceutical company reported ($0.35) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.42) by $0.07. EyeGate Pharmaceuticals has generated ($1.77) earnings per share over the last year (($1.68) diluted earnings per share). Earnings for EyeGate Pharmaceuticals are expected to grow in the coming year, from ($1.52) to ($1.48) per share. EyeGate Pharmaceuticals has not formally confirmed its next earnings publication date, but the company’s estimated earnings date is Monday, November 8th, 2021 based off prior year’s report dates.

IS EYEGATE PHARMACEUTICALS A BUY RIGHT NOW? (NASDAQ:EYEG)

2 Wall Street analysts have issued “buy,” “hold,” and “sell” ratings for EyeGate Pharmaceuticals in the last twelve months. There are currently 2 buy ratings for the stock. The consensus among Wall Street analysts is that investors should “buy” EyeGate Pharmaceuticals stock.
EyeGate Pharmaceuticals

TRANSCONTINENTAL REALTY INVESTORS EARNINGS ESTIMATES AND ACTUALS BY QUARTER (NYSE:TCI)

WHAT STOCKS DOES MARKETBEAT LIKE BETTER THAN TRANSCONTINENTAL REALTY INVESTORS? (NYSE:TCI)

Wall Street analysts have given Transcontinental Realty Investors a “N/A” rating, but there may be better buying opportunities in the stock market. Some of MarketBeat’s past winning trading ideas have resulted in 5-15% weekly gains. MarketBeat just released five new stock ideas, but Transcontinental Realty Investors wasn’t one of them. MarketBeat thinks these five companies may be even better buys.